Article
Impact of concurrent genetic alterations on outcomes after allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Cancer letters - 28 Oct 2026
Sun Yao, Liu Jing, Chen Jia, Xuan Li, Liu Jia, Fan Meng-Lin, Lu Sheng-Ye, Xu Lan-Ping, Zhang Xi, Liu Qi-Fa, Wu De-Pei, Huang Xiao-Jun, Liu Dai-Hong
Abstract excerpt
TP53 mutations confer poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Inconsistent definitions of TP53 allelic status and limited access to routine testing impede accurate prognostic risk stratification for this high-risk myeloid population. This multicenter retrospective cohort study analyzed 303 patients...
Read the complete abstract on PubMedTopics
- Humans
- Myelodysplastic Syndromes
- Hematopoietic Stem Cell Transplantation
- Leukemia, Myeloid, Acute
- Mutation